|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
|
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Current assets | ||||||
| Cash | ||||||
| Prepaid expenses and other current assets | ||||||
| Prepaid expenses | ||||||
| Receivable from related party | ||||||
| Total current assets | ||||||
| Cash and marketable securities held in Trust Account | ||||||
| Interest receivable on cash and marketable securities held in Trust Account | ||||||
| Other long-term assets | ||||||
| TOTAL ASSETS | ||||||
| LIABILITIES, REDEEMABLE COMMON STOCK AND STOCKHOLDERS’ DEFICIT | ||||||
| Current liabilities | ||||||
| Accounts payable | ||||||
| Accrued liabilities | ||||||
| Payable to related parties | ||||||
| Notes payable to related party | ||||||
| Other current liabilities | ||||||
| Total current liabilities | ||||||
| Warrant liability | ||||||
| Deferred underwriting fee payable | ||||||
| Total liabilities | ||||||
| Common stock subject to possible redemption, 4,223,437 shares and 20,900,000 shares as of September 30, 2022 and December 31, 2021, respectively, at a redemption value of $10.10 per share | ||||||
| Stockholders’ deficit | ||||||
| Common stock, par value of $0.0001 per share; 100,000,000 shares authorized; 6,184,000 shares issued and outstanding (excluding 4,223,437 and 20,900,000 shares subject to possible redemption as of September 30, 2022 and December 31, 2021, respectively) | ||||||
| Additional paid-in capital | ||||||
| Accumulated deficit | ||||||
| Total stockholders’ deficit | ||||||
| TOTAL LIABILITIES, REDEEMABLE COMMON STOCK AND STOCKHOLDERS’ DEFICIT |
Loading...
